AUTHORS
Maria Sirenko, Ph.D., Juan Balandran, PhD2, Ayana Sawai-Frantz, PhD3, Sachiko Keane4, Ziyan Lin5, Amy Wang6, Chloe Palmer7, Sanam Loghavi, MD8, Samuel Magaziner, MPhil9, Jerome Hadjadj Jr, MD PhD10, Deborah Rivera11, Bhavisha A Patel, MD12, Emma Groarke, MD13, Peter Grayson, MD14, Iannis Aifantis, PhD15, David Beck, MD, PhD16
AFFILIATIONS
1 NYU Grossman School of Medicine, New York, New York, United States, NYU Grossman School of Medicine, New York, New York, United States, NYU Grossman School of Medicine, New York, New York, United States
2 NYU Grossman School of Medicine, New York, New York, United States, NYU Grossman School of Medicine, New York, New York, United States
3 NYU Grossman School of Medicine, New York, New York, United States
4 NYU Grossman School of Medicine, New York, New York, United States
5 NYU Grossman School of Medicine, New York, New York, United States
6 NYU Grossman School of Medicine, New York, New York, United States
7 National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, Maryland, United States
8 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 NYU Grossman School of Medicine, New York, New York, United States
10 NYU Grossman School of Medicine, New York, New York, United States, Sorbonne Université, Internal Medicine Department, Saint Antoine Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France
11 NYU Grossman School of Medicine, New York, New York, United States
12 National Institutes of Health, National Heart, Lung, and Blood Institute (NHLBI), Bethesda, Maryland, United States
13 National Institutes of Health, National Heart, Lung, and Blood Institute (NHLBI), Bethesda, Maryland, United States
14 National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, Maryland, United States
15 NYU Grossman School of Medicine, New York, New York, United States, NYU Grossman School of Medicine, New York, New York, United States
16 NYU Grossman School of Medicine, New York, New York, United States, NYU Grossman School of Medicine, New York, New York, United States, NYU Grossman School of Medicine, New York, New York, United States
ABSTRACT
Background:
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a late-onset autoinflammatory disease caused by somatic mutations in UBA1 characterized by cytopenias and systemic inflammation. Although VEXAS is initiated by somatic UBA1 mutations in hematopoietic stem and progenitor cells (HSPCs), the downstream effector populations linking UBA1 dysfunction to inflammatory disease remain incompletely defined.
Methods:
We integrated multimodal profiling of patient samples with functional assays and genetic modeling. To investigate which immune populations are altered in VEXAS syndrome, we performed immunoprofiling by spectral flow cytometry on peripheral blood (PB) from patients (n=15) and age-matched controls (n=8). Negatively isolated neutrophils from matched bone marrow (BM) and PB were profiled by 10X Genomics 3’ kits (n=22 patients, 5 controls). To model mutant hematopoiesis, UBA1M41T-edited human CD34+ hematopoietic stem and progenitor cells were engrafted into NSG-S mice. We further generated conditional mouse models of Uba1 loss, including neutrophil-restricted deletion using Mrp8-cre, and evaluated inflammatory phenotypes, cytokine output, neutrophil state, and dependency on neutrophils and PAD4-mediated NETosis in vivo.
Results:
Immunoprofiling of VEXAS patients revealed a striking expansion of neutrophils with an immature phenotype (CD10 and CD13 low) with increased expression of activation-associated markers (IFITM1, IL-18Rα, HLA-ABC, and HLA-DR). We next investigated whether neutropoiesis was altered in VEXAS patients using single-cell transcriptomic profiling. In the BM, neutrophils spanned a differentiation continuum from immature precursors to mature populations. Control neutrophils expressed a homeostatic/regulatory program across differentiation states that was diminished in VEXAS. Instead, mature VEXAS neutrophils upregulated activated, inflammatory, and chemotactic signatures. In PB, neutrophils were predominantly mature. We identified three mature PB neutrophil expression modules shared across VEXAS patients: an adhesion/stress-responsive activated program, an NF-κB/CXCL8-high inflammatory program, and an interferon-stimulated program. VEXAS neutrophils also upregulated a NETosis program. To determine whether these transcriptional changes reflected functional abnormalities, we assessed migration and NETosis. In an in vitro chemotaxis assay assessing migration toward IL-8, VEXAS neutrophils demonstrated enhanced migratory capacity. Furthermore, VEXAS neutrophils exhibited increased NET (neutrophil extracellular trap) formation capacity after in vitro activation, as demonstrated by increased DAPI?MPO?CitH3? cells compared to controls. Together, the immunoprofiling, transcriptional, and functional data demonstrate that neutrophils in VEXAS are hyperactivated and have enhanced capacity for migration and NETosis.
To establish an in vivo disease model, we first used humanized xenografts with UBA1M41T HSPCs, which generated neutrophil-enriched progeny and reduced B-cell output. However, this model had impaired engraftment and did not induce systemic inflammation. Thus, we modeled Uba1 loss directly in neutrophils via Mrp8-cre mediated deletion. Neutrophil-specific Uba1 deletion recapitulated key inflammatory features of VEXAS, including spontaneous dermatitis, neutrophilia, and elevated inflammatory cytokines, including IL6, TNF, and, IL-1?. Single-cell transcriptomic analysis revealed expansion of a mature neutrophil population that upregulated interferon, IL6 JAK/STAT, unfolded protein response, migration, and NETosis programs, mirroring human disease. Functionally, Uba1-deficient neutrophils displayed enhanced NET formation in vitro. Since neutrophilic dermatosis is a prominent manifestation of VEXAS, we next confirmed the accumulation of pathogenic neutrophils in skin lesions, with increased DAPI?MPO?CitH3?. In an MC903-inducible dermatitis model, both neutrophil depletion and pharmacologic PAD4 inhibition significantly attenuated tissue inflammation, nominating neutrophils and NETosis as potential therapeutic targets in VEXAS.
Conclusions:
These data establish neutrophils as central inflammatory effectors in VEXAS patients and murine models, thus resolving the missing link between UBA1 mutation and systemic inflammation. We further establish a robust and tractable murine model of VEXAS and nominate the neutrophil/NETosis axis as a driver and therapeutic vulnerability in VEXAS.
DISCLOSURES
Maria Sirenko, Ph.D.: No relevant conflicts of interest to declare.